

## Clinical Trials Directory

### Directory of Novartis Translational Medicine Clinical Studies

#### Accordion:

Acne

## Moderate to Severe Inflammatory Acne

### NCT03497897

The purpose of the study is to evaluate the tolerability and efficacy of LYS006 in patients with moderate to severe inflammatory acne.

View this study on [ClinicalTrials.gov](#) <sup>[1]</sup>

Active Overuse Tendinopathy

## Active Overuse Tendinopathy

### NCT03344640

The purpose of the study is to investigate if AIN457 (secukinumab) can help heal the tendon in patients who have shoulder tendinopathy.

View this study on [ClinicalTrials.gov](#) <sup>[2]</sup>

APDS

## APDS

## Activated PI3 kinase Delta Syndrome (APDS) / PASLI

### NCT02435173

The purpose of this study is to assess the effectiveness, tolerability and pharmacokinetics of CDZ173 in patients with APDS/PASLI (activated phosphoinositide 3-kinase delta syndrome/ p110 $\gamma$ -activating mutation causing senescent T cells, lymphadenopathy and

immunodeficiency).

View this study on [ClinicalTrials.gov](#) [3]

## **Activated PI3 kinase Delta Syndrome (APDS) / PASLI**

### **NCT02859727**

This study is an open-label extension and enrollment is open to patients who have completed study CCDZ173X2201 (NCT02435173). The purpose of this study is to obtain long term safety, tolerability, efficacy and pharmacokinetic data.

View this study on [ClinicalTrials.gov](#) [4]

Articular Cartilage Lesions

## **Articular Cartilage Lesions**

### **NCT03275064**

The purpose of the study is to investigate whether LNA043 is tolerated in patients with articular cartilage lesions and if it promotes the regeneration of the articular cartilage tissue.

View this study on [ClinicalTrials.gov](#) [5]

Asthma

## **Asthma**

## **Inadequately Controlled Severe Asthma**

### **NCT03299686**

The purpose of this study is to determine the effectiveness and tolerability of CJM112 when added to an existing therapy in patients with inadequately controlled moderate to severe asthma.

View this study on [ClinicalTrials.gov](#) [6]

Autologous Chondrocyte Implantation (ACI)

## **Autologous Chondrocyte Implantation (ACI)**

### **NCT03334812**

The purpose of this study is to investigate the tolerability and preliminary effectiveness of LNA043 administered by intra-articular injection in regenerating the articular cartilage of the knee in patients undergoing autologous chondrocyte implantation.

View this study on [ClinicalTrials.gov](#) [7]

Chronic Hemodialysis And Anemia

## **Chronic Hemodialysis And Anemia**

### **NCT02570854**

The purpose of this study is to determine the dose of CSJ137 that is tolerated while also improving blood iron levels and blood hemoglobin levels.

View this study on [ClinicalTrials.gov](#) [8]

Cocaine Use Disorder

## **Cocaine Use Disorder**

### **NCT03242928**

The purpose of the study is to investigate whether AFQ056 is effective in reducing cocaine use in patients diagnosed with cocaine use disorder (CUD).

View this study on [ClinicalTrials.gov](#) [9]

Depression

## **Depression**

### **NCT03756129**

The purpose of this study is to determine if MIJ821 is effective for patients with treatment-resistant depression.

View this study on [ClinicalTrials.gov](#) [10]

Hearing Loss

## **Hearing Loss**

### **NCT02132130**

The purpose of this study is to evaluate the tolerability and the potential ability of CGF166 to improve hearing and balance (vestibular function).

View this study on [ClinicalTrials.gov](#) <sup>[11]</sup>

Idiopathic Pulmonary Fibrosis

## **Idiopathic Pulmonary Fibrosis**

### **NCT03287414**

The purpose of the study is to determine if VAY736 will improve lung function in people who have been diagnosed with IPF.

View this study on [ClinicalTrials.gov](#) <sup>[12]</sup>

Intracerebral Hemorrhage (ICH)

## **Intracerebral Hemorrhage (ICH)**

### **NCT03338998**

The purpose of this study is to see if BAF312 is an effective and tolerated treatment for patients with ICH, also known as hemorrhagic stroke.

View this study on [ClinicalTrials.gov](#) <sup>[13]</sup>

Kidney Disease

## **Kidney Disease**

### **C3 Glomerulopathy**

#### **NCT03832114**

The purpose of this study is to investigate the effectiveness, tolerability and pharmacokinetics of LNP023 in patients with C3 Glomerulopathy

View this study on [ClinicalTrials.gov](#) <sup>[14]</sup>

## **Diabetic Nephropathy**

### **NCT03804879**

The purpose of this study is to evaluate the effectiveness and tolerability of LMB763 in patients with diabetic nephropathy.

View this study on [ClinicalTrials.gov](#) [15]

## **IgA Nephropathy**

### **NCT03373461**

The purpose of the study is to investigate the tolerability and effectiveness of LNP023 in patients who have IgA nephropathy.

View this study on [ClinicalTrials.gov](#) [16]

Lupus

## **Lupus**

## **Lupus Nephritis**

### **NCT03610516**

The purpose of this study is to investigate the effectiveness, tolerability, pharmacokinetics and pharmacodynamics of CFZ533X in patients with moderately active lupus nephritis.

View this study on [ClinicalTrials.gov](#) [17]

## **Systemic Lupus Erythematosus (SLE)**

### **NCT03656562**

The purpose of the study is to evaluate the tolerability and efficacy of CFZ533 and VAY736 in patients with systemic lupus erythematosus.

View this study on [ClinicalTrials.gov](#) [18]

Non-alcoholic Steatohepatitis (NASH)

## **Non-alcoholic Steatohepatitis (NASH)**

### **NCT03205150**

The purpose of the study is to investigate whether LIK066 is tolerated and has beneficial effects in reducing liver fat and inflammation in patients with non-alcoholic steatohepatitis (NASH) and increased body weight. The study will measure blood levels of alanine

aminotransferase (ALT), which is a test used to detect liver injury.

View this study on [ClinicalTrials.gov](#) [19]

Obesity

## **Obesity**

### **NCT03466203**

The purpose of the study is to evaluate the tolerability of LLF580.

View this study on [ClinicalTrials.gov](#) [20]

Paroxysmal Nocturnal Hemoglobinuria (PNH)

## **Paroxysmal Nocturnal Hemoglobinuria (PNH)**

### **NCT03439839**

The purpose of the study is to evaluate if LNP023 is effective in reducing the damage to red blood cells.

View this study on [ClinicalTrials.gov](#) [21]

Retinitis Pigmentosa

## **Retinitis Pigmentosa**

### **NCT03374657**

The purpose of the study is to investigate whether CPK850 is tolerated in patients with RLBP1 retinitis pigmentosa to explore dose levels throughout the study, and determine if it is effective in improving vision in patients with impaired vision.

View this study on [ClinicalTrials.gov](#) [22]

Schizophrenia

## **Schizophrenia**

**NCT03751280**

The purpose of this study is to investigate the efficacy of PEAR-004 in patients with schizophrenia

View this study on [ClinicalTrials.gov](#) [23]

Sickle Cell Anemia

**Sickle Cell Anemia****NCT02961218**

The purpose of the study is to determine if ACZ885 (canakinumab) will reduce daily pain and inflammation of adolescent and young adult patients with sickle cell anemia.

View this study on [ClinicalTrials.gov](#) [24]

---

**Featured image:**



**Footnotes:**

All studies are investigational. Safety and efficacy have not been proven.

.field-name-field-top-body h2 { margin-top:0px !important }

**Hero title:**

Novartis Translational Medicine Featured Clinical Studies

---

**Source URL:** <https://www.earlydevtrials.novartis.com/clinical-trials-directory>



## Links

- [1] <https://clinicaltrials.gov/ct2/show/NCT03497897>
- [2] <https://clinicaltrials.gov/ct2/show/NCT03344640>
- [3] <https://clinicaltrials.gov/ct2/show/NCT02435173>
- [4] <https://clinicaltrials.gov/ct2/show/NCT02859727>
- [5] <https://clinicaltrials.gov/ct2/show/NCT03275064>
- [6] <https://clinicaltrials.gov/ct2/show/NCT03299686>
- [7] <https://clinicaltrials.gov/ct2/show/NCT03334812>
- [8] <https://clinicaltrials.gov/ct2/show/NCT02570854>
- [9] <https://clinicaltrials.gov/ct2/show/NCT03242928>
- [10] <https://clinicaltrials.gov/ct2/show/NCT03756129>
- [11] <https://clinicaltrials.gov/ct2/show/NCT02132130>
- [12] <https://clinicaltrials.gov/ct2/show/NCT03287414>
- [13] <https://clinicaltrials.gov/ct2/show/NCT03338998>
- [14] <https://clinicaltrials.gov/ct2/show/NCT03832114>
- [15] <https://clinicaltrials.gov/ct2/show/NCT03804879>
- [16] <https://clinicaltrials.gov/ct2/show/NCT03373461>
- [17] <https://clinicaltrials.gov/ct2/show/NCT03610516>
- [18] <https://clinicaltrials.gov/ct2/show/NCT03656562>
- [19] <https://clinicaltrials.gov/ct2/show/NCT03205150>
- [20] <https://clinicaltrials.gov/ct2/show/NCT03466203>
- [21] <https://clinicaltrials.gov/ct2/show/NCT03439839>
- [22] <https://clinicaltrials.gov/ct2/show/NCT03374657>
- [23] <https://clinicaltrials.gov/ct2/show/NCT03751280>
- [24] <https://clinicaltrials.gov/ct2/show/NCT02961218>